Menu
ETF
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow-10.45 M CAD-4.96 M CAD-5.88 M CAD-4.88 M CAD-3.99 M CAD-2.66 M CAD-3.01 M CAD-2.52 M CAD-1.55 M CAD-660856 CAD-1.50 M CAD-515817 CAD
Depreciation & Amortization51225 CAD42448 CAD145397 CAD102718 CAD111718 CAD112750 CAD60550 CAD2307 CAD1488 CAD619 CAD0 CAD
Stock-Based Compensation859494 CAD492236 CAD170382 CAD752591 CAD410007 CAD122015 CAD256051 CAD97002 CAD
Capital Expenditures24646 CAD43014 CAD33748 CAD49192 CAD0 CAD646183 CAD0 CAD3094 CAD0 CAD
Cash Flow from Investing-243019 CAD-188605 CAD-169610 CAD-180640 CAD193880 CAD-26843 CAD-769165 CAD-155399 CAD-9699 CAD-20102 CAD684817 CAD-76286 CAD
Cash Flow from Financing6.05 M CAD10.32 M CAD1.59 M CAD-44600 CAD13.42 M CAD2.70 M CAD3.33 M CAD1.87 M CAD4.00 M CAD514292 CAD373255 CAD1.23 M CAD
Dividends Paid
Stock Buybacks
Free Cash Flow-10.48 M CAD-5.00 M CAD-5.91 M CAD-4.93 M CAD-2.66 M CAD-3.65 M CAD-1.55 M CAD-663950 CAD-1.50 M CAD

Lexaria Bioscience Corp. is a biotechnology company focused on enhancing the delivery of bioactive compounds, including cannabinoids and nicotine, through its proprietary drug delivery platform, DehydraTECH. The primary function of this platform is to improve the speed and efficiency of oral absorption of active pharmaceutical ingredients, with potential applications extending across a wide range of industries, including pharmaceuticals, nutraceuticals, consumer packaged goods, and more. Lexaria's technology aims to provide alternative product formulations that offer improved bioavailability and taste masking without altering the stimulant properties of the active compounds. By operating at the intersection of drug development and consumer health, the company plays a pivotal role in advancing innovative delivery solutions, contributing to the growing market of next-generation wellness products. Lexaria Bioscience Corp. continues to partner with organizations intent on developing products that integrate its advanced technology, seeking to capitalize on emerging markets where efficient delivery systems for bioactive substances are increasingly in demand.